Why Your EU Food Supplement Dossier Won't Get You a Canadian NPN — And What Actually Will

Every few months, a European supplement brand contacts us after receiving a product licence refusal from Health Canada. The story is almost always the same: they had a clean EU notification on file, high-quality lab reports from a reputable European testing house, and an EFSA-consistent safety summary. They assumed that translated into a credible Canadian application. It didn’t.

Canada’s Natural Health Products (NHP) regime is not a mirror image of Europe’s Food Supplements Directive. The regulatory philosophies are fundamentally different — and the evidence standards diverge in ways that simply aren’t visible until you’re already inside the review queue.

The EU Notification Model vs. Canada’s Pre-Market Licence

In most EU member states, placing a food supplement on the market means notifying the relevant competent authority — the DGCCRF in France, the BfR in Germany, the FNPIS in Poland. You notify, and unless you receive a formal objection, you sell. The burden of proof shifts to you only if a question is raised post-market.

Health Canada does not work that way. Under Canada’s Natural Health Products Regulations (SOR/2003-196), you must receive a product licence — carrying an assigned NPN (Natural Product Number) — before a single unit crosses a Canadian border or appears on a Canadian shelf. There is no notification pathway. The application is reviewed, and Health Canada can ask questions, request additional evidence, or refuse outright.

That review takes time. Standard applications carry a statutory 300-day review timeline. Applications that meet the specifications of a Health Canada compendial monograph qualify for an accelerated 60-day track. The difference between those two pathways almost always comes down to how precisely the product was formulated and dosed against the NHPID (Natural Health Products Ingredients Database) monograph for each active ingredient.

This structural difference alone catches most EU brands off guard. They’ve operated in a post-market accountability model for years and haven’t had to build a pre-submission evidence file before their first sale. Suddenly they’re in a pre-authorization system, and their existing dossier wasn’t built for it.

Where Your EU Evidence Package Falls Short

The gaps are predictable. And because they’re predictable, they’re fixable — but only if you know where to look before you file.

Traditional use thresholds are incompatible

If your product contains a botanical ingredient and you’ve been relying on traditional use status in Europe — particularly under Directive 2004/24/EC on traditional herbal medicinal products — your threshold is 30 years of documented use, with at least 15 of those years within the EU. Health Canada’s traditional evidence standard for NHP applications requires at least 150 years of documented traditional use, with at least 50 of those years in a country with a Western lifestyle and healthcare system comparable to Canada’s. That’s a completely different order of magnitude.

An EU traditional use file rarely satisfies Health Canada reviewers without substantial supplementation from ethnobotanical literature, historical pharmacopoeial references, and third-party documentation of use across multiple generations. Many brands discover this only after their application is returned with a clarification request.

EFSA opinions aren’t Health Canada opinions

EFSA’s safety opinions are rigorous and internationally respected. But they’re European. Health Canada’s evidence reviewers assess data against NHPID monograph specifications — and EFSA’s recommended intake values don’t always align with Canadian dose limits.

Consider vitamin B6 (pyridoxine): the EU’s tolerable upper intake level guidance and Health Canada’s NHP monograph specify different maximum daily doses. A product formulated at the upper end of the EU range can exceed the Health Canada limit, triggering either a mandatory dose reduction that changes your formulation entirely, or a requirement to submit clinical evidence justifying the higher dose. Neither is a quick fix after your application is already in review.

Laboratory methodology and accreditation gaps

Your EU certificates of analysis most likely reference Ph.Eur. (European Pharmacopoeia) methods. Health Canada accepts Ph.Eur., USP, and BP — so this isn’t inherently a blocking issue. But if your testing was conducted by a laboratory that isn’t ISO 17025 accredited, or if the analytical methods applied aren’t compendial for that specific substance, Health Canada reviewers will request supplementary test data. Some European facilities, particularly those operating under food-safety GMP frameworks rather than ISO 17025 environments, generate COAs that look complete but lack the method validation documentation Health Canada expects. The application stalls.

Labelling claims don’t cross the Atlantic

EU health claims authorized under Regulation (EC) No 1924/2006 and Canadian NHP “Recommended Use” statements are entirely separate systems with virtually no formal overlap. A claim that’s on the EU authorized list carries no presumption of validity in Canada. Canadian NHP labelling must include the NPN number, the recommended use or purpose in exact language matching the product licence, the recommended dose, and all risk information specified in the Health Canada monograph. Brands that draft their Canadian label from their EU label template almost invariably end up with at least one non-compliant claim that delays approval.

What Health Canada Actually Wants to See

The fastest route to a Canadian NPN is formulating your product to a Health Canada compendial monograph from the start. NHPID currently contains entries for over 900 medicinal ingredients, each specifying permitted dose ranges, dosage forms, permitted claim statements, and associated cautions and warnings. If your product matches a monograph — correct ingredient form, dose within range, claim matching the permitted language — you qualify for the 60-day review track rather than the 300-day standard timeline. That difference alone can determine whether you make a retail buyer’s next product cycle or miss it by months.

For products containing ingredients not covered by existing NHPID monographs, or dosed outside monograph ranges, you’ll need an evidence dossier. Health Canada accepts three evidence categories: traditional evidence (meeting the 150-year threshold), systematic literature review/meta-analysis, or clinical trial data. For botanical products that fall outside the traditional use threshold, a systematic review of published literature — assessed for quality, relevance to your specific claim, and applicability to your target population — is the most practical route.

Product quality documentation is non-negotiable regardless of the evidence pathway. Every application must include:

• Specifications for each medicinal and non-medicinal ingredient, including identity, potency, and purity limits
• Testing methods (compendial or validated, with validation data if non-compendial)
• Evidence of GMP compliance for every site involved in manufacture, packaging, labelling, and importation — each requiring its own site licence
• A finished product specification covering identity, potency, microbial limits, and physical characteristics

One detail that routinely surprises European manufacturers: the Canadian importer is a licensed site under NHP regulations. If you’re shipping finished goods to a Canadian distributor who imports on your behalf, that distributor needs an NHP site licence specifically covering importation. Their compliance status becomes part of your product’s regulatory standing in Canada. It’s worth confirming the licensing status of any prospective Canadian partner before committing to a distribution arrangement.

Building a Dossier That Works in Both Markets

With deliberate formulation design, a supplement can satisfy both EU and Canadian requirements simultaneously. But it has to be planned before formulation, not after.

The critical decisions happen at the ingredient selection and dosing stage. Choose ingredients that appear in both the EU positive lists under Directive 2002/46/EC (Annexes I and II cover 13 vitamins and 15 mineral substances) and NHPID monographs, and formulate within the overlapping dose ranges. For botanicals, cross-reference the EU’s traditional use botanical list with Health Canada monographs at product conception — not after your formulation is locked.

Testing strategy needs to be designed for both markets from the outset as well. Selecting an ISO 17025 accredited laboratory that routinely tests against both Ph.Eur. and USP methods means your COA supports both EU notification and Health Canada’s quality evidence requirements from the same document set. Our cross-continental partner-lab network is specifically structured to make this possible: a European lab coordinating with a USP/AOAC-capable facility in North America generates test data that is regulator-ready on both sides of the Atlantic without duplicating your testing budget.

Canada’s NHP market is worth approximately CAD $6 billion annually and has shown consistent year-on-year growth. The regulatory pathway is genuinely accessible — but it demands understanding that it functions as a pharmaceutical-style, pre-authorization model, not an EU-style notification. European brands that approach Health Canada with that mindset in place make the transition cleanly. Those that assume their existing dossier will travel intact do not.

The most practical step you can take today: pull your three best-selling products, look up each active ingredient in the NHPID, and compare your formulated dose against the permitted dose range in the corresponding monograph. That exercise takes an afternoon and will immediately tell you whether each product is on the 60-day track or the 300-day track — and which formulations need to change before you even think about filing.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Ready to map your supplement portfolio against Health Canada’s NHP requirements? Contact us

Related from our network

• Natural Health Product Testing in Canada — ISO 17025 Accredited — Androxa provides NHP-specific testing services in Canada, generating COA data to Health Canada compendial standards for USP, Ph.Eur., and BP methods.
• Supplement Testing Lab for US Market Entry — Qalitex Laboratories offers ISO 17025 accredited supplement testing against USP and AOAC methods, generating data accepted by FDA and NHPD reviewers alike.